RxDoctor Payments Data

Derek Shafer, MD

Family Medicine · Omaha, NENPI 1568810711

Payments from drug & device makers

$267in general payments, 2019–2025

Across 14 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$43
  • AbbVie$41
  • Lundbeck LLC$24
  • Takeda Pharmaceuticals U.S.A., Inc.$24
  • Xeris Pharmaceuticals, Inc.$22
  • Merck$22
  • plus $91 from 6 others

What the payments were for

  • Food & beverage$267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$267 in reported general payments places this provider in the 35th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,887
Medicare patients
16
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$107,788
EliquisApixaban102$67,989
JardianceEmpagliflozin60$45,973
XareltoRivaroxaban44$27,894
Bydureon BciseExenatide Microspheres26$20,751
JanuviaSitagliptin Phosphate21$12,310
MounjaroTirzepatide11$11,213
Fiasp FlextouchInsulin Aspart (Niacinamide)15$8,680
MyrbetriqMirabegron18$8,657
Breo ElliptaFluticasone/Vilanterol20$8,242
Tresiba Flextouch U-100Insulin Degludec13$7,296
Janumet XrSitagliptin Phos/Metformin Hcl12$6,291
TradjentaLinagliptin12$5,340
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,881
Fentanyl28$3,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$107,788108 claims
MerckJanuvia, Janumet Xr$22$18,60133 claims
Lilly USA, LLCMounjaro$43$11,21311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →